



**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER
ENDED JUNE 30, 2016.**

SR. NO.	PARTICULARS	3 Months Ended 30/06/2016	3 Months Ended 31/03/2016	3 Months Ended 30/06/2015	3 Months Ended 31/03/2016
		(Un-Audited)	Audited	(Audited)	Audited (9 M)
1	Income from Operations Net Sales/Income from Operations & Other Operating Income (net of Excise Duty)	3,783.26	3,576.85	14,195.82	25,345.48
2	Total Income from Operations (net)	3,783.26	3,576.85	14,195.82	25,345.48
	Expenses				
	(a) Cost of Material Consumed	2,190.43	2,732.20	13,329.67	20,726.18
	(b) Purchase of Stock-in-trade	-	-	510.21	355.66
	(c) Change in Inventories of Finished Goods, Work-in-progress and Stock in trade	13,925.35	12,278.84	(1,803.85)	12,143.34
	(d) Employee benefit Expense	555.31	560.57	362.71	1,654.61
	(e) Depreciation & Ammortisation Expense	502.64	501.13	553.70	1,501.46
	(f) Other Expenses	939.47	2,034.74	1,270.99	3,849.63
	Total Expenses	18,113.20	18,107.47	14,223.43	40,230.87
3	Profit from Operations before Other Income, Finance Cost & Exceptional Items (1-2)	(14,329.93)	(14,530.62)	(27.61)	(14,885.39)
4	Other Income	48.64	56.26	119.26	194.93
5	Profit from Ordinary activities before Finance Cost & Exceptional Items (3+4)	(14,281.29)	(14,474.36)	91.65	(14,690.46)
6	Finance Cost	1,358.00	3,631.84	4,975.35	7,098.15
7	Profit from Ordinary activities after Finance Cost & Exceptional Items (5-6)	(15,639.30)	(18,106.20)	(4,883.70)	(21,788.61)
8	Exceptional Items	2,298.92	(3,725.70)	3,825.24	7,135.21
9	Profit from Ordinary activities before Tax (7-8)	(17,938.22)	(14,380.51)	(8,708.94)	(28,923.82)
10	Tax Expense	-	996.57	(466.36)	996.57
11	Net Profit (+) / Loss (-) from Ordinary Activities after tax (9-10)	(17,938.22)	(15,377.08)	(8,242.58)	(29,920.39)
12	Extraordinary items (net of tax expense)	(17,938.22)	(15,377.08)	(8,242.58)	(29,920.39)
13	Net Profit (+) / Loss (-) for the period (11 -12)	(17,938.22)	(15,377.08)	(8,242.58)	(29,920.39)
14	Other Comprehensive Income	-	-	-	-
15	Total Comprehensive Income (13+14)	(17,938.22)	(15,377.08)	(8,242.58)	(29,920.39)
16	Paid up Equity Share Capital (Face value of Rs. 2/- each)	2,378.71	2,378.71	2,378.71	2,378.71
17	Reserves excluding Revaluation Reserves	-	-	-	(21,899.66)
18	Earnings Per Share (of Rs.2/- each) (not annualised)	(15.08)	(12.93)	(6.93)	(25.16)
	a) Basic (in Rs.)	(14.74)	(12.64)	(6.77)	(24.59)
	b) Diluted (in Rs.)				

1) The above results for the quarter ended June 30, 2016 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on August 11, 2016.


2) The Statutory Auditors of the Company has carried out the Limited Review of the above standalone results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

3) The company has not provided for interest amounting to Rs. 1386 Lacs on Loans for the quarter ended 30 June 2016, in view of the same has not been charged by various banks.

4) Previous years figures have been re-grouped and re-arranged wherever considered necessary.

Place : Mumbai.
Date : 11.08.2016

For Sharon Bio-Medicine Ltd.


Savita Gowda
Managing Director.

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001
www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships